Some bad news from Cambridge-based Tolerx Inc.: The biotechnology company and a partner, GlaxoSmithKline PLC, report their experimental drug for Type 1 diabetes failed to meet the main clinical goal of a late-stage study.
The 272-patient study measured how well newly diagnosed adults were able to improve production of insulin a year after an eight-day course of the treatment, a monoclonal antibody called otelixizumab. The goal was for patients to show a change in a measure of insulin production called C-peptide.
The companies are reviewing the results but have suspended recruitment and dosing of a separate late-stage trial of the treatment.
via boston.com
No comments:
Post a Comment